GHRP-6 increases growth hormone release in human experiments. This does not demonstrate that it builds muscle, repairs a tendon or makes recovery safer. No controlled trial identified for this analysis supports these goals in healthy adults.
The trap is a bait and switch: measure a hormone, then sell a sports result. The lab measured a signal. The shop adds biceps.
In France, no medicine containing GHRP-6 was found in the medicinal product and composition files of the Public Medicines Database consulted on 11 October 2026. This search has a specific scope, detailed below. In sport, the answer is clear: the World Anti-Doping Agency’s 2026 list explicitly names GHRP-6 among substances prohibited at all times.
GHRP-6: what molecule are we talking about?
GHRP-6, short for growth hormone-releasing peptide-6, is a synthetic peptide made up of six amino acids. It is a secretagogue: it stimulates the body’s secretion of GH. It is neither pharmaceutical GH, nor an anabolic steroid, nor a dietary supplement with established benefits for sport.
Its action involves the GHSR-1a receptor, also called the ghrelin receptor. Ghrelin plays a role in hunger signals and GH regulation. Activating its receptor therefore does not isolate a “muscle growth” switch.
GHRP-2 and ipamorelin target a related set of mechanisms, but they are different molecules. Their results, side effects and exposures are not interchangeable. To put this distinction in the context of the sports market, the guide to peptides for muscle building and their risks covers the main families.
Also watch out for references discussing [D-Lys3]-GHRP-6: this variant is used as an experimental receptor antagonist. A paper that blocks a pathway with this tool does not demonstrate the benefits of GHRP-6, which activates it. Similar name, different scientific question.
GH and hunger: a mechanism is not a clinical benefit
In a 1998 experiment involving nine healthy men aged 20 to 30, blocking endogenous GHRH greatly reduced the GH response to GHRP-6. This experiment shows an interaction with existing hormonal regulation. It measures no improvement in sports performance.
The distinction is simple: a blood concentration describes an endocrine response. To demonstrate hypertrophy, you need to measure muscle tissue. To demonstrate recovery, you need to define an outcome: return of strength, resumption of activity, pain or healing, with an appropriate comparator and duration.
Three separate questions
GH, hunger and recovery do not measure the same thing
- GH: hormonal response observed in humans
- Hunger: plausible mechanism, human data mainly on GHRP-2
- Muscle and recovery: GHRP-6 benefit not established in healthy adults
Why does its reputation revolve around appetite?
In rats, a 2005 study of central administration of GHRP-6 reports increased food intake and body weight. This is animal evidence, under experimental conditions far removed from human use.
For human food intake, a GHRP-2 trial involving 19 lean or obese participants observed an increase in the amount eaten at a meal compared with placebo. This trial concerns GHRP-2, not GHRP-6. It supports interest in this pathway for research, without allowing vials to be ranked by their effect on your hunger.
Eating more does not guarantee muscle gain or an appropriate diet either. Presenting an appetite signal as evidence of recovery adds another shortcut. If you have a persistent lack of appetite or are losing weight unintentionally, the useful question is what is causing it, not which peptide to add.
What human studies actually measured
The table deliberately separates hormonal tests from clinical research. Some publications are accessible here only through their indexed abstracts: this particularly limits detailed assessment of adverse events and methods.
Here are the studies that directly inform the claim:
| Study | Population and setting | Outcome measured and relevant finding | Limitation for muscle building |
|---|---|---|---|
| Frieboes et al., 1995 | Healthy men, overnight comparison with placebo | Changes in GH, ACTH, cortisol and sleep electroencephalogram | Acute experiment, no results on hypertrophy or sports recovery |
| Borges et al., 1997 | Six patients with endogenous hypercortisolism, nine exposed to excess glucocorticoids, ten controls | GH response differed according to endocrine context | Tests on separate days, no training or muscle gain assessed |
| Mechanistic study, 1998 | Nine healthy men, GHRP-6 with or without a GHRH antagonist | Marked reduction in GH response with the antagonist | Describes regulation, not clinical efficacy |
| Hernández-Bernal et al., 2024 | 36 patients after ischaemic stroke, EGF + GHRP-6 or usual care | Safety and neurological or functional scores, exploratory favourable signals | Combination of two substances, small open-label trial, hospital setting |
| COURAGE-2, 2026 | 188 patients after stroke, EGF + GHRP-6 combination versus usual care | Primary endpoint not met, exploratory findings in subgroups | Neither GHRP-6 alone nor healthy athletes, exploratory results requiring confirmation |
Clinical research exists, but it does not establish benefits for sports recovery
Saying “no human studies” would be wrong. The exploratory post-stroke trial even assessed clinical outcomes. However, the lack of blinding, small sample size and a deviation from the initial allocation weaken its interpretation. Several authors are affiliated with the centre that formulated the experimental products. The publication declares no commercial or financial conflict of interest.
The phase III COURAGE-2 publication is particularly useful for avoiding stopping at the first encouraging result: it found no difference in the main outcomes in the intention-to-treat population. Subgroup findings do not rescue a missed primary endpoint. And none of these trials separates the effect of GHRP-6 from that of EGF.
The conclusion therefore concerns sports use, not every line of research: the data reviewed do not support proposing a GHRP-6 cycle to build muscle or recover. Hospital protocols are not templates for self-medication.
Risks: separating signals from unknowns
A product that acts on GH does not act only on the muscle you are targeting. The 1995 overnight experiment also observed changes in ACTH and cortisol. A one-off hormonal increase is not enough to diagnose a disease, but it contradicts the promise of a strictly targeted effect.
The FDA specifically identifies concerns for GHRP-6 involving cortisol and increased blood glucose linked to reduced insulin sensitivity. It also flags a risk of immunogenicity, particularly associated with aggregates and peptide impurities, and limited safety information. This US warning provides information on risks. It does not define French law or establish how often these risks occur in athletes.
Three levels must remain distinct:
- Observed or reported: hormonal responses and metabolic concerns identified in the available data.
- Plausible but not quantified for this use: immune reactions and complications associated with an injectable product of uncertain composition.
- Unknown: safety of prolonged use, consequences of combinations and actual risk in populations excluded from trials.
Not noticing a problem resolves none of these unknowns. It measures neither insulin sensitivity nor product quality. Conversely, the evidence reviewed does not support asserting that GHRP-6 causes cancer in humans.
Is ipamorelin a safe alternative?
A 1998 pharmacological study describes GH selectivity for ipamorelin in pigs, with less ACTH and cortisol stimulation than the GHRPs compared. The authors worked at Novo Nordisk. This preclinical difference does not demonstrate greater safety over months in humans, still less the safety of a commercial mixture.
The analysis of ipamorelin and CJC-1295 explains why “more selective” does not mean “validated protocol”.
An HPLC certificate does not make a vial fit for injection
HPLC is a chromatography method. A purity result describes certain chemical parameters of the sample analysed using a given method. It is not a microbiological check.
The ICH Q6A pharmaceutical specifications distinguish identity, content, impurities and product-specific tests. Endotoxin tests answer a different question from chromatography or testing for viable microorganisms. A product may therefore require several independent checks.
To read a certificate without imagining it proves more than it does, check the following questions:
- Does the analysed sample correspond to the batch and vial received?
- Were identity and quantity tested, or only relative purity?
- Does the document contain separate sterility and endotoxin results?
- Are stability and transport conditions documented?
Even documented answers do not create authorisation for human administration. This checklist explains an analytical limitation, not a method for choosing a supplier. The guide to peptide certificates, contamination and sterility · FR explores these checks in more depth.
Status in France and anti-doping: verification dated 11 October 2026
What was checked, and what the search does not prove
The files CIS_bdpm.txt and CIS_COMPO_bdpm.txt, available on the official download page and dated 29 September 2026, were searched for the terms GHRP, GHRP-6, GHRP 6, growth hormone releasing and hexapeptide. No matches were found.
The BDPM mainly covers medicines currently marketed or recently discontinued. This check therefore does not constitute exhaustive proof of the absence of any historical authorisation, research authorisation or exceptional access. No French medicine containing GHRP-6 for muscle building or recovery was identified.
The ANSM warning dated 2 July 2026, reproduced by the French National Order of Pharmacists, calls on people not to buy or use unauthorised peptides sold outside official channels with uncertain composition. The direct ANSM page was not accessible during this verification. This general warning does not attribute every adverse incident to GHRP-6.
The French Public Health Code, Article L. 5121-8, requires authorisation for placing medicinal products on the market. An accessible shop and a “research use only” label do not demonstrate authorisation as a medicine. The precise status of importation, sale or possession depends on the product and the applicable framework: the absence of marketing authorisation is not enough to automatically make all possession an offence.
Three statuses that are not interchangeable
Here is a useful framework to avoid confusing health, research and sport:
| Question | What must be established | What this does not prove |
|---|---|---|
| Medicine | Authorisation, indication, prescribing conditions and pharmaceutical supply channel | Authorisation for one use does not validate muscle building |
| Research product | Experimental purpose and applicable research framework | Sale of a reagent does not authorise its administration to a person |
| Doping | Anti-doping rules applicable to the athlete and the substance concerned | A molecule being studied or medically useful is not automatically permitted in sport |
The 2026 WADA list, section S2.2.4, names GHRP-6, GHRP-2 and ipamorelin. They are prohibited in and out of competition. This rule does not depend on evidence of muscle gain. For an actual medical situation, speak to your doctor and the relevant anti-doping organisation before any use.
Questions to ask a professional
If the promise of recovery appeals to you, start by defining the problem: persistent fatigue, reduced strength, localised pain or lack of appetite do not call for the same assessment. A single GH measurement does not, on its own, show that you need treatment.
Prepare a few concrete questions for the consultation:
- What cause should we look for behind my symptoms or lack of progress?
- Which study measures the outcome I care about in a comparable population?
- Does the proposed product have an authorised indication and supply channel in France?
- Which treatments and aspects of my medical history change the risk assessment?
Pregnancy, breastfeeding, being underage, diabetes, endocrine disease or a history of tumours make personal experimentation with an unauthorised product particularly unjustified. This is not a list of contraindications taken from a GHRP-6 Summary of Product Characteristics: no corresponding French Summary of Product Characteristics was identified.
To work on recovery, first return to factors you can observe: training progression, adequate nutrition, sleep and injury management. The guide to assessing your sleep without a tracker helps clarify one concrete factor. If pain persists, a diagnosis and appropriate rehabilitation are worth more than a blanket promise of repair.
After using a suspect vial, keep the packaging and tell the healthcare professional what the product was, when you used it and what other substances you took. Fever or spreading redness requires prompt medical attention. Difficulty breathing, facial swelling or loss of consciousness means you must call 15 or 112.
The Verdict
Main sources
The older endocrine trials were consulted through their indexed abstracts. The full text of the 2024 stroke trial and the indexed abstract of COURAGE-2 were consulted. Institutional documents provide a different context, explicitly distinguished from athletic use:
